The impact of osteopontin gene variations on multiple sclerosis development and progression

Cristoforo Comi, Giuseppe Cappellano, Annalisa Chiocchetti, Elisabetta Orilieri, Sara Buttini, Laura Ghezzi, Daniela Galimberti, Franca Guerini, Nadia Barizzone, Franco Perla, Maurizio Leone, Sandra D'Alfonso, Domenico Caputo, Elio Scarpini, Roberto Cantello, Umberto Dianzani

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Osteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5′ end on the - 156 G > GG single nucleotide polymorphism (SNP) and replicated our previous findings at the 3′ end on the + 1239 A > C SNP. We found that only + 1239 A > C SNP displayed a statistically significant association with MS development, but both + 1239 A > C and - 156 G > GG had an influence on MS progression, since patients homozygous for both +1239A and -156GG alleles displayed slower progression of disability and slower switch to secondary progression than those carrying +1239C and/or -156G and those homozygous for +1239A only. Moreover, patients homozygous for +1239A also displayed a significantly lower relapse rate than those carrying +1239C, which is in line with the established role of OPN in MS relapses.

Original languageEnglish
Article number212893
JournalClinical and Developmental Immunology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Osteopontin
Multiple Sclerosis
Single Nucleotide Polymorphism
Genes
Recurrence
Causality
Alleles

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Comi, C., Cappellano, G., Chiocchetti, A., Orilieri, E., Buttini, S., Ghezzi, L., ... Dianzani, U. (2012). The impact of osteopontin gene variations on multiple sclerosis development and progression. Clinical and Developmental Immunology, 2012, [212893]. https://doi.org/10.1155/2012/212893

The impact of osteopontin gene variations on multiple sclerosis development and progression. / Comi, Cristoforo; Cappellano, Giuseppe; Chiocchetti, Annalisa; Orilieri, Elisabetta; Buttini, Sara; Ghezzi, Laura; Galimberti, Daniela; Guerini, Franca; Barizzone, Nadia; Perla, Franco; Leone, Maurizio; D'Alfonso, Sandra; Caputo, Domenico; Scarpini, Elio; Cantello, Roberto; Dianzani, Umberto.

In: Clinical and Developmental Immunology, Vol. 2012, 212893, 2012.

Research output: Contribution to journalArticle

Comi, C, Cappellano, G, Chiocchetti, A, Orilieri, E, Buttini, S, Ghezzi, L, Galimberti, D, Guerini, F, Barizzone, N, Perla, F, Leone, M, D'Alfonso, S, Caputo, D, Scarpini, E, Cantello, R & Dianzani, U 2012, 'The impact of osteopontin gene variations on multiple sclerosis development and progression', Clinical and Developmental Immunology, vol. 2012, 212893. https://doi.org/10.1155/2012/212893
Comi, Cristoforo ; Cappellano, Giuseppe ; Chiocchetti, Annalisa ; Orilieri, Elisabetta ; Buttini, Sara ; Ghezzi, Laura ; Galimberti, Daniela ; Guerini, Franca ; Barizzone, Nadia ; Perla, Franco ; Leone, Maurizio ; D'Alfonso, Sandra ; Caputo, Domenico ; Scarpini, Elio ; Cantello, Roberto ; Dianzani, Umberto. / The impact of osteopontin gene variations on multiple sclerosis development and progression. In: Clinical and Developmental Immunology. 2012 ; Vol. 2012.
@article{6bc55207440a40d1aa6707a5acb8ebd6,
title = "The impact of osteopontin gene variations on multiple sclerosis development and progression",
abstract = "Osteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5′ end on the - 156 G > GG single nucleotide polymorphism (SNP) and replicated our previous findings at the 3′ end on the + 1239 A > C SNP. We found that only + 1239 A > C SNP displayed a statistically significant association with MS development, but both + 1239 A > C and - 156 G > GG had an influence on MS progression, since patients homozygous for both +1239A and -156GG alleles displayed slower progression of disability and slower switch to secondary progression than those carrying +1239C and/or -156G and those homozygous for +1239A only. Moreover, patients homozygous for +1239A also displayed a significantly lower relapse rate than those carrying +1239C, which is in line with the established role of OPN in MS relapses.",
author = "Cristoforo Comi and Giuseppe Cappellano and Annalisa Chiocchetti and Elisabetta Orilieri and Sara Buttini and Laura Ghezzi and Daniela Galimberti and Franca Guerini and Nadia Barizzone and Franco Perla and Maurizio Leone and Sandra D'Alfonso and Domenico Caputo and Elio Scarpini and Roberto Cantello and Umberto Dianzani",
year = "2012",
doi = "10.1155/2012/212893",
language = "English",
volume = "2012",
journal = "Clinical and Developmental Immunology",
issn = "1740-2522",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The impact of osteopontin gene variations on multiple sclerosis development and progression

AU - Comi, Cristoforo

AU - Cappellano, Giuseppe

AU - Chiocchetti, Annalisa

AU - Orilieri, Elisabetta

AU - Buttini, Sara

AU - Ghezzi, Laura

AU - Galimberti, Daniela

AU - Guerini, Franca

AU - Barizzone, Nadia

AU - Perla, Franco

AU - Leone, Maurizio

AU - D'Alfonso, Sandra

AU - Caputo, Domenico

AU - Scarpini, Elio

AU - Cantello, Roberto

AU - Dianzani, Umberto

PY - 2012

Y1 - 2012

N2 - Osteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5′ end on the - 156 G > GG single nucleotide polymorphism (SNP) and replicated our previous findings at the 3′ end on the + 1239 A > C SNP. We found that only + 1239 A > C SNP displayed a statistically significant association with MS development, but both + 1239 A > C and - 156 G > GG had an influence on MS progression, since patients homozygous for both +1239A and -156GG alleles displayed slower progression of disability and slower switch to secondary progression than those carrying +1239C and/or -156G and those homozygous for +1239A only. Moreover, patients homozygous for +1239A also displayed a significantly lower relapse rate than those carrying +1239C, which is in line with the established role of OPN in MS relapses.

AB - Osteopontin is a proinflammatory molecule, modulating TH1 and TH17 responses. Several reports suggest its involvement in multiple sclerosis (MS) pathogenesis. We previously reported that OPN gene variations at the 3′ end are a predisposing factor for MS development and evolution. In this paper, we extended our analysis to a gene variation at the 5′ end on the - 156 G > GG single nucleotide polymorphism (SNP) and replicated our previous findings at the 3′ end on the + 1239 A > C SNP. We found that only + 1239 A > C SNP displayed a statistically significant association with MS development, but both + 1239 A > C and - 156 G > GG had an influence on MS progression, since patients homozygous for both +1239A and -156GG alleles displayed slower progression of disability and slower switch to secondary progression than those carrying +1239C and/or -156G and those homozygous for +1239A only. Moreover, patients homozygous for +1239A also displayed a significantly lower relapse rate than those carrying +1239C, which is in line with the established role of OPN in MS relapses.

UR - http://www.scopus.com/inward/record.url?scp=84867344577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867344577&partnerID=8YFLogxK

U2 - 10.1155/2012/212893

DO - 10.1155/2012/212893

M3 - Article

VL - 2012

JO - Clinical and Developmental Immunology

JF - Clinical and Developmental Immunology

SN - 1740-2522

M1 - 212893

ER -